Clinical trials are also anticipated to repurpose tocilizumab, a clinically approved drug used for the treatment of autoimmune diseases such as arthritis, to improve the prognosis of patients with cancers displaying CIN and activated IL-6-STAT3 signaling. This evidence concerns the gene IL6 and cervical squamous intraepithelial neoplasia.